
Marc R Radke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7652159/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2019, 9, 210-219.	9.4	278
2	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. Clinical Cancer Research, 2020, 26, 4268-4279.	7.0	126
3	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nature Communications, 2019, 10, 5661.	12.8	45
4	Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer. Cancer Research, 2020, 80, 857-867.	0.9	33
5	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical Cancer Research, 2021, 27, 6314-6322.	7.0	22
6	Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer, 2021, 3, zcab028.	3.1	20
7	Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. Gynecologic Oncology, 2021, 160, 786-792.	1.4	17
8	Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. Science Translational Medicine, 2022, 14, .	12.4	15
9	Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma. Gynecologic Oncology, 2020, 156, 407-414.	1.4	10
10	Molecular phylogenetics and species-level systematics of Baylisascaris. International Journal for Parasitology: Parasites and Wildlife, 2018, 7, 450-462.	1.5	8
11	Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation. Journal of Physical Education and Sports Management, 2021, 7, a006083.	1.2	5
12	DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma. Pancreas, 2021, 50, e50-e52.	1.1	1